Fluorene-Based p-Conjugated Oligomers
FULL PAPER
pumped by the Spitfire regenerative amplifier were used so that the laser
wavelength could be tuned for optimum excitation.
40.0, 34.7, 31.1, 26.0, 26.0, 25.9, 23.0, 22.9, 13.8 ppm; MS (FAB): m/z:
1860.1 [M+].
p-Ph2N-OF(5)-TAZ: The synthetic procedure for compound 3 was fol-
lowed using compound 4a (158.5 mg, 0.1 mmol), compound 5 (97.9 mg,
Compound 3a: A mixture of 1a (1.10 g, 0.84 mmol), compound 2 (0.49 g,
1.26 mmol), palladium(II) acetate (10 mg, 0.045 mmol), triACTHNUTRGNE(UNG o-tolyl)phos-
0.2 mmol), palladium(II) acetate (1.2 mg, 0.005 mmol), triACTHNUTRGNE(UNG o-tolyl)phos-
phine (28 mg, 0.092 mmol), 2m K2CO3 (2 mL), toluene (25 mL), and
methanol (10 mL) under a nitrogen atmosphere was heated at 758C over-
night with good magnetic stirring. After cooling to room temperature,
the reaction mixture was poured into water and extracted with ethyl ace-
tate (30 mL) followed by dichloromethane (30 mL). The combined or-
ganic layer was dried over anhydrous Na2SO4, evaporated to dryness, and
the residue was purified by silica gel column chromatography using 8:1
dichloromethane/ethyl acetate as eluent, thereby affording 3a (1.20 g,
93%) as a white solid. 1H NMR (400 MHz, CDCl3, 258C): d=7.76–7.83
(m, 7H), 7.46–7.73 (m, 24H), 7.36–7.38 (m, 2H), 7.30 (d, J=6.4 Hz, 2H),
7.25 (d, J=7.2 Hz, 2H), 2.04–2.10 (m, 16H), 1.28 (s, 9H), 1.09–1.18 (m,
16H), 0.68–0.79 (m, 40H), 0.33 ppm (s, 9H); 13C NMR (100 MHz,
CDCl3, 258C): d=154.8, 154.4, 152.7, 151.7, 151.6, 150.1, 142.5, 141.3,
140.6, 140.4, 140.3, 140.0, 139.9, 139.7, 139.0, 138.7, 135.5, 131.8, 130.0,
129.6, 129.0, 128.3, 128.0, 127.5, 126.9, 126.0, 125.6, 125.3, 123.9, 121.4,
121.2, 120.0, 119.9, 118.9, 55.2, 55.0, 40.2, 39.9, 34.7, 31.1, 26.1, 26.0, 23.0,
23.0, 13.8, 13.7, ꢀ0.8 ppm; MS (FAB): m/z: 1530.2 [M+].
phine (3.1 mg, 0.01 mmol), 2mK2CO3 (1 mL), toluene (10 mL), and meth-
anol (4 mL). The crude product was purified by silica gel column chroma-
tography using 8:1 dichloromethane/ethyl acetate as an eluent, thereby
affording p-Ph2N-OF(5)-TAZ (153 mg, 80%) as a light yellow solid.
1H NMR (400 MHz, CDCl3, 258C): d=7.77–7.85 (m, 8H), 7.49–7.72 (m,
27H), 7.38 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 7.24–7.32 (m,
4H), 7.15 (d, J=8.0 Hz, 5H), 7.00–7.06 (m, 3H), 1.90–2.37 (m, 20H),
1.29 (s, 9H), 1.03–1.19 (m, 20H), 0.68–0.80 ppm (m, 50H); 13C NMR
(100 MHz, CDCl3, 258C): d=154.8, 154.4, 152.8, 152.3, 151.7, 151.4,
147.9, 147.1, 142.5, 140.6, 140.6, 140.4, 140.1, 140.0, 139.9, 139.8, 139.7,
139.5, 138.7, 135.9, 135.5, 130.0, 129.6, 129.1, 129.0, 128.3, 128.0, 126.9,
126.0, 125.6, 125.3, 123.9, 123.8, 123.4, 122.4, 121.4, 121.2, 121.1, 120.3,
120.0, 119.9, 119.3, 55.2, 55.0, 40.2, 39.9, 34.7, 31.1, 26.0, 23.0, 23.0, 13.8,
13.8 ppm; HRMS (MALDI-TOF): m/z: 1903.2173 [M++H]; elemental
analysis calcd (%) for C141H152N4: C 89.00, H 8.05, N 2.94; found: C
88.97, H 7.76, N 2.94.
p-Ph2N-OF(6)-TAZ: The synthetic procedure for compound 3 was fol-
lowed using compound 4b (531 mg, 0.29 mmol), compound 5 (279 mg,
0.57 mmol), palladium(II) acetate (3.2 mg, 0.014 mmol), triACTHNUTRGNE(UNG o-tolyl)phos-
Compound 3b: The synthetic procedure for compound 3a was followed
using compound 1b (158.5 mg, 0.1 mmol), compound
2
(58.3 mg,
0.15 mmol), palladium(II) acetate (1.1 mg, 0.005 mmol), triAHCTUNGRETG(NNUN o-tolyl)phos-
phine (8.7 mg, 0.029 mmol), 2mK2CO3 (1.5 mL), toluene (20 mL), and
methanol (8 mL). The crude product was purified by silica gel column
chromatography using 8:1 dichloromethane/ethyl acetate as an eluent,
thereby affording 530 mg (80%) of a yellow solid. 1H NMR (400 MHz,
CDCl3, 258C): d=7.76–7.84 (m, 10H), 7.47–7.70 (m, 33H), 7.35 (d, J=
8.8 Hz, 2H), 7.29 (d, J=8.4 Hz, 2H), 7.22–7.24 (m, 2H), 2.13 (m, 6H),
6.98–7.04 (m, 4H), 2.09 (m, 24H), 1.27 (s, 9H), 1.01–1.14 (m, 24H), 0.66–
0.78 ppm (m, 60H); 13C NMR (100 MHz, CDCl3, 258C): d=154.8, 154.4,
152.8, 152.3, 151.8, 151.4, 147.9, 147.1, 142.5, 140.6, 140.4, 140.1, 140.0,
139.8, 139.7, 139.5, 138.7, 135.9, 135.5, 130.0, 129.6, 129.1, 129.0, 128.3,
128.0, 126.9, 126.1, 125.6, 125.4, 123.9, 123.8, 123.4, 122.4, 121.4, 120.3,
120.0, 119.9, 119.3, 55.2, 55.0, 40.2, 40.0, 34.7, 31.1, 26.1, 23.1, 23.0, 13.8,
13.8 ppm; HRMS (MALDI-TOF): m/z: 2179.4032 [M++H]; elemental
analysis calcd (%) for C162H176N4: C 89.29, H 8.14, N 2.57; found: C
89.55, H 8.13, N 2.56.
phine (3.2 mg, 0.01 mmol), 2m K2CO3 (1 mL), toluene (10 mL), and
methanol (4 mL). The crude product was purified by silica gel column
chromatography using 8:1 dichloromethane/ethyl acetate as an eluent,
thereby affording 3b (153 mg, 80%) as a light yellow solid. 1H NMR
(400 MHz, CDCl3, 258C): d=7.77–7.85 (m, 8H), 7.46–7.74 (m, 29H),
7.38 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.8 Hz, 2H), 7.24–7.27 (m, 2H), 2.03–
2.09 (m, 20H), 1.27 (s, 9H), 1.08–1.18 (m, 20H), 0.66–0.78 (m, 50H),
0.31 ppm (s, 9H); 13C NMR (100 MHz, CDCl3, 258C): d=154.8, 154.4,
152.8, 151.7, 151.7, 151.6, 150.1, 142.5, 141.3, 140.6, 140.6, 140.4, 140.3,
140.3, 140.0, 140.0, 139.9, 139.7, 139.0, 138.7, 135.5, 131.8, 130.0, 129.6,
129.0, 128.3, 127.9, 127.5, 126.9, 126.0, 125.9, 125.6, 125.3, 123.9, 121.4,
121.2, 120.0, 119.9, 118.9, 55.2, 55.0, 40.2, 39.9, 34.7, 31.1, 26.1, 26.0, 23.0,
23.0, 23.0, 13.8, 13.7, ꢀ0.86 ppm; MS (FAB): m/z: 1806.3 [M+].
Compound 4a: A mixture of 3a (1.09 g, 0.71 mmol), silver trifluoroace-
tate (0.24 g, 1.1 mmol), and iodine (0.22 g, 0.85 mmol) in chloroform
(30 mL) was heated to reflux and stirred for 4 h. After cooling to room
temperature, the mixture was poured into sodium sulfite solution and ex-
tracted with dichloromethane (3ꢀ30 mL). The combined organic layer
was dried over anhydrous Na2SO4 and evaporated to dryness. The crude
product was purified by short silica gel column chromatography using 8:1
dichloromethane/ethyl acetate as eluent, thereby affording the iodide 4a
as a light yellow solid (1.06 g, 94%). 1H NMR (400 MHz, CDCl3, 258C):
d=7.81–7.84 (m, 9H), 7.45–7.71 (m, 24H), 7.37 (d, J=8.8, 2H), 7.30 (d,
J=8.8, 2H), 7.23–7.25 (m, 2H), 1.95–2.13 (m, 16H), 1.28 (s, 9H), 1.07–
1.18 (m, 16H), 0.65–0.78 ppm (m, 40H); 13C NMR (100 MHz, CDCl3,
258C): d=154.8, 154.4, 153.4, 152.8, 150.8, 142.5, 141.0, 140.6, 140.6,
140.4, 140.3, 140.3, 140.1, 140.0, 139.9, 139.9, 139.7, 139.2, 138.7, 135.8,
135.5, 132.0, 130.0, 129.6, 129.0, 128.3, 128.0, 126.9, 126.1, 126.1, 125.6,
125.3, 123.9, 121.4, 121.2, 120.0, 119.9, 92.4, 55.3, 55.2, 40.2, 40.0, 34.7,
31.1, 26.0, 26.0, 25.9, 23.0, 23.0, 13.8 ppm; MS (FAB): m/z: 1583.9 [M+].
Compound 8: The synthetic procedure for compound 3 was followed
using compound 6 (609 mg, 1.41 mmol), 2-thiopheneboronic acid (7;
360 mg, 2.81 mmol), palladium(II) acetate (11 mg), triACTHNUGRTENUNG(o-tolyl)phosphine
(26 mg), toluene (15 mL), methanol (6 mL), and 2mK2CO3 (2 mL). The
crude product was purified by silica gel column chromatography using
8:1 dichloromethane/ethyl acetate as an eluent, thereby affording
8
(468 mg, 82%) as a yellow solid. 1H NMR (400 MHz, CDCl3, 258C): d=
7.05–7.50 (m, 16H), 1.28 ppm (s, 9H); 13C NMR (67 MHz, CDCl3, 258C):
d=154.6, 154.0, 143.0, 135.1, 129.8, 129.5, 128.9, 128.1, 128.0, 127.7, 125.6,
125.4, 125.2, 123.7, 123.6, 117.6, 34.7, 31.1 ppm; MS (FAB): m/z: 435.9
[M+].
Compound 9: A mixture of compound 8 (271 mg, 0.62 mmol) and NBS
(133 mg, 0.75 mmol) in chloroform was heated at reflux overnight. The
reaction mixture washed with brine, dried over anhydrous sodium sulfate,
and evaporated in vacuum. The residue was purified by silica gel column
chromatography using 8:1 dichloromethane/ethyl acetate as an eluent,
1
Compound 4b: The iodo-desilylation procedure for compound 4a was
followed using compound 3b (547 mg, 0.30 mmol), iodine (92 mg,
0.36 mmol), silver trifluoroacetate (100 mg, 0.45 mmol), and chloroform
(20 mL). The crude product was purified by silica gel column chromatog-
raphy using 8:1 dichloromethane/ethyl acetate as an eluent, thereby af-
fording 4b (530 mg, 85%) as a yellow solid. 1H NMR (400 MHz, CDCl3,
258C): d=7.75–7.84 (m, 9H), 7.48–7.71 (m, 28H), 7.37 (d, J=8.4 Hz,
2H), 7.30 (d, J=8.4 Hz, 2H), 7.25 (d, J=7.6 Hz, 2H), 2.03–2.11 (m,
20H), 1.28 (s, 9H), 1.09–1.17 (m, 20H), 0.68–0.80 ppm (m, 50H);
13C NMR (100 MHz, CDCl3, 258C): d=154.8, 154.4, 153.3, 152.7, 150.8,
142.5, 141.0, 140.6, 140.5, 140.3, 140.1, 139.9, 139.9, 139.7, 139.2, 138.7,
135.8, 135.5, 132.0, 130.0, 129.6, 129.0, 128.3, 127.9, 126.9, 126.1, 126.0,
125.6, 125.3, 123.9, 121.4, 121.2, 121.2, 120.0, 119.9, 92.4, 55.3, 55.2, 40.1,
thereby affording 9 (468 mg, 87%) as a yellow solid. H NMR (400 MHz,
CDCl3, 258C): d=7.02–7.49 (m, 15H), 1.28 ppm (s, 9H); 13C NMR
(67 MHz, CDCl3, 258C): d=154.6, 153.8, 152.6, 144.3, 135.1, 134.2, 130.8,
129.8, 129.5, 128.9, 128.1, 127.7, 126.0, 125.2, 125.0, 123.7, 123.6, 112.1,
34.7, 31.0 ppm; MS (FAB): m/z: 516.1 [M+].
p-Ph2N-OFOT-TAZ: The synthetic procedure for compound 3 was fol-
lowed using compound 9 (400 mg, 0.78 mmol), compound 5 (571 mg,
1.17 mmol), palladium(II) acetate (20 mg), triACTHNUTRGNE(NUG o-tolyl)phosphine (45 mg),
2mK2CO3 (3 mL), toluene (20 mL), and methanol (8 mL). The crude
product was purified by silica gel column chromatography using 8:1 di-
chloromethane/ethyl acetate as an eluent, thereby affording p-Ph2N-
OFOT-TAZ (560 mg, 82%) as
CDCl3, 258C): d=7.34–7.61 (m, 16H), 7.23–7.27 (m, 7H), 7.11–7.14 (m,
a
yellow solid. 1H NMR (400 MHz,
Chem. Eur. J. 2009, 15, 11681 – 11691
ꢁ 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
11689